cas 69843-13-6, 1-Methyl-1H-pyrazol-4-ylamine

Articles about 69843-13-6Total 40 be found

Article title
Article abstract
Author
Journal number and time
Download

Light-Triggered, Non-Centrosymmetric Self-Assembly of Aqueous Arylazopyrazoles at the Air–Water Interface and Switching of Second-Harmonic Generation
Trans-p-methoxy arylazopyrazole spontaneously forms non-centrosymmetric polar crystals, which reversibly undergo liquefaction upon photoisomerization to the cis-isomer. This liquid cis-isomer has a large electric dipole moment and is highly soluble in water (solubility up to ≈58 mM), which is remarkably higher than that of the trans-isomer (690 μM). Vis-light illumination of the aqueous cis-isomer generates macroscopically oriented, non-centrosymmetric crystals at the air–water interface. Polar crystals are also formed in sandwich glass cells (spacing, 20 μm) upon photo-induced crystallization of the liquid cis-isomer. The trans-crystals thus formed showed second harmonic generation (SHG) whose intensity is switched on/off in response to the photo-induced phase transition.
Nagai, Yuki,Ishiba, Keita,Yamamoto, Ryosuke,Yamada, Teppei,Morikawa, Masa-aki,Kimizuka, Nobuo
supporting information
p. 6333 - 6338
(2021/02/16)

Design and synthesis of anti-tumor compounds containing ferulic acid-pyrazole skeleton
The invention discloses design and a preparation method of an anti-tumor compound containing a ferulic acid-pyrazole skeleton. The structure of the anti-tumor compound is shown as a formula in the specification.
-
Paragraph 0024-0025; 0029; 0031-0032; 0035

(2021/04/28)

Kilogram-Scale Preparation of an Aminopyrazole Building Block via Copper-Catalyzed Aryl Amidation
We describe a scalable method for preparing an aminopyrazole building block using copper-catalyzed amidation with acetamide as an ammonia surrogate. This procedure provides an alternative to the standard nitration/reduction sequence and avoids energetic intermediates, specialized hydrogenation equipment, and potentially genotoxic impurities that arise from nitro reduction. The chemistry has been successfully scaled to produce >50 kg of the target compound and demonstrate the viability of this alternative route.
Baldwin, Aaron F.,Caporello, Michaella A.,Chen, Guoyong,Goetz, Adam E.,Hu, Weifeng,Jin, Chengfeng,Knopf, Kevin M.,Li, Zhifeng,Lu, Cuong V.,Monfette, Sebastien,Puchlopek-Dermenci, Angela L. A.,Shi, Feng
supporting information
p. 1065 - 1073
(2021/05/04)

Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis
Selective JAK3 inhibitors have been shown to have a potential benefit in the treatment of autoimmune disorders. Here we report the identification of a series of pyrazolopyrimidine derivatives as potent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Most of these compounds (13k, 13n and 13 t), displayed stronger anti-JAK3 kinase activity and selectivity than tofacitinib. Furthermore, the most active inhibitor 13t (IC50 = 0.1 nM), also exhibited favourable selectivity for JAK3 in a panel of 9 kinases which contain the same cysteine. In a series of cytokinestimulated cellular analysis, compound 13 t, could potently block the JAK3-STAT signaling pathway. Further biological studies, including cellular antiproliferative activity assays and a rat adjuvant-induced arthritis model for in vivo evaluation, also indicated its efficacy and low toxicity in the treatment of rheumatoid arthritis. The results of these experimental explorations suggested that 13t is a promising lead compound for the development of selective JAK3 inhibitor with therapeutic potential in rheumatoid arthritis.
Chen, Cheng-Juan,Shu, Lei,Wang, Zhi-Jian,Yin, Yuan,Yu, Ru-Nan,Zhang, Da-Yong,Zhang, Tian-Tai
(2020/03/17)

Alkynyl pyrimidine or alkynyl pyridine compound as well as composition and application thereof
The invention relates to alkynyl pyrimidine or alkynyl pyridine compounds represented by a formula (I) or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof. The invention also discloses a pharmaceutical composition contain
-
Paragraph 0073; 0074; 0076

(2020/08/18)

Preparation method and application of novel 6-amino-1H-pyrazolo[3,4-d]pyrimidine JAK kinase inhibitors
The present invention provides drugs used for preventing, treating and/or ameliorating autoimmune diseases (such as psoriasis, rheumatoid arthritis, inflammatory enteritis diseases, Sjogren's syndrome, Behcet's disease, multiple sclerosis and systemic lupus erythematosus). The drugs have excellent JAK kinase inhibitory activity. The present invention also provides pharmaceutically acceptable compositions including the above compounds, and methods for preparing the compounds.
-
Paragraph 0240; 0283-0292

(2020/03/29)

Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors
Janus kinases (JAKs) play a key role in the proliferation, apoptosis and differentiation of immune cells, and JAKs are considered as an attractive target for the treatment of inflammatory and autoimmune diseases. Here we show the design and optimization of pyrimidine-4,6-diamine derivatives as selectivity JAK3 inhibitors. Compound 11e, which might interact with unique cysteine (Cys909) residue in JAK3, exhibited excellent JAK3 inhibitory activity (IC50 = 2.1 nM) and high JAK kinase selectivity. In cellular assay, 11e showed moderate potency inhibiting IL-2-stimulated T cell proliferation. The data supports the further development of novel JAKs inhibitors.
Yu, Ru-Nan,Chen, Cheng-Juan,Shu, Lei,Yin, Yuan,Wang, Zhi-Jian,Zhang, Tian-Tai,Zhang, Da-Yong
p. 1646 - 1657
(2019/03/08)

Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents
A series of 7H-pyrrolo[2,3-d]pyrimidine derivatives possessing a dimethylphosphine oxide moiety were designed, synthesized and evaluated as novel Focal adhesion kinase (FAK) inhibitors. Most compounds potently suppressed the enzymatic activities of FAK, with IC50 values in the 10?8–10?9 M range, and potently inhibited the proliferation of breast (MDA-MB-231) and lung (A549) cancer cell lines. The representative compound 25b exhibited potent enzyme inhibition (IC50 = 5.4 nM) and good selectivity when tested on a panel of 26 kinases. 25b exhibited antiproliferative activity against A549 cells (IC50 = 3.2 μM) and relatively less cytotoxicity to a normal human cell line HK2. Compound 25b also induced apoptosis and suppressed the migration of A549 cells in a concentration-dependent manner. Further profiling of compound 25b revealed it had good metabolic stability in mouse, rat and human liver microsomes in vitro and showed weak inhibitory activity against various subtypes of human cytochrome P450. The docking study of compound 25b was performed to elucidate its possible binding modes and to provide a structural basis for further structure-guided design of FAK inhibitors.
Wang, Ruifeng,Chen, Yixuan,Zhao, Xiangxin,Yu, Sijia,Yang, Bowen,Wu, Tianxiao,Guo, Jing,Hao, Chenzhou,Zhao, Dongmei,Cheng, Maosheng
(2019/09/30)

Preparation and application of novel 4,6-disubstituted aminopyrimidine JAK (janus kinase) inhibitor
The invention discloses preparation and application of novel 4,6-disubstituted aminopyrimidine JAK (janus kinase) inhibitors, and provide drugs which can be used for preventing, treating and/or improving autoimmune diseases (for example, psoriasis, rheumatoid arthritis, inflammatory enteritis diseases, Jagren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), and have excellent JAK inhibitory activity. The invention also provides pharmaceutically acceptable composition containing the compounds and methods for preparing the compounds.
-
Paragraph 0202-0207; 0218-0222

(2019/05/08)

Design of potent B-RafV600E inhibitors by multiple copy simulation search strategy
B-Raf kinase is a vital intermedium in the mitogen-activated protein kinase (MAPK) signaling pathway, which transforms extracellular signals into cellular mechanisms. Mutations in this kinase, for instance, the most common V600E mutation, can lead to the ERK signaling pathologically activated and hence cause severe diseases such as somatic tumors. So far, the development of B-Raf inhibitors has made remarkable progress. However, the resistance and relapse of approved Raf drugs have been widely reported, and the optimization for old drugs and the discovery for new inhibitors still remain a significant task. In this study, we designed and evaluated a series of novel B-RafV600E inhibitors. A fragment library has been established before the docking simulation carried out using the MCSS strategy (multicopy simulation search). The appropriate fragments were reassembled to provide new candidate compounds, which were further screened by iterative docking simulations and molecular dynamics. Bioassays were carried out to evaluate the pharmacological profile of the compounds identified and synthesized. The result showed that compound 5n had an impressive enzyme inhibitory and antiproliferation activity, suggesting a promising potential in the future study.
Wang, Ze-Feng,Wang, Peng-Fei,Ma, Jun-Ting,Chai, Ying-Zi,Hu, Hui-Min,Gao, Wen-Long,Wang, Zhong-Chang,Wang, Bao-Zhong,Zhu, Hai-Liang
p. 567 - 574
(2017/12/26)

Identification and Biological Evaluation of Novel Type II B-RafV600E Inhibitors
The mitogen-activated protein kinase (MAPK) pathway plays a vital role in signal transduction networks. Severe diseases may be triggered if it is disturbed by mutated components, especially the kinase B-RafV600E. New inhibitors of the kinase ar
Wang, Peng-Fei,Wang, Ze-Feng,Qiu, Han-Yue,Huang, Yue,Hu, Hui-Min,Wang, Zhong-Chang,Zhu, Hai-Liang
p. 2558 - 2566
(2018/11/23)

Design, synthesis, and biological evaluation of pyrazole derivatives containing acetamide bond as potential BRAFV600E inhibitors
With the increasingly acquired resistance, relapse and side effects of known marketed BRAFV600E inhibitors, it's significant to design the more effective and novel drugs. In this study, a series of novel pyrazole derivatives containing acetamid
Wang, Chen-Ru,Wang, Ze-Feng,Shi, Lu,Wang, Zhong-Chang,Zhu, Hai-Liang
supporting information
p. 2382 - 2390
(2018/06/25)

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF
Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.
-
Paragraph 0133-0134

(2018/08/12)

Heteroaromatic compound and application thereof to drug
The invention discloses a heteroaromatic compound and application thereof to drug. In particular, the invention provides a heteroaromatic compound or stereoisomers thereof, geometric isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, and a pharmaceutical composition comprising the compound provided by the invention. The invention also discloses application of the compound provided by the invention or the pharmaceutical composition thereofto preparation of a medicine for reatment of autoimmune diseases or proliferative diseases.
-
Paragraph 0453; 0806; 0807; 0808

(2017/07/31)

Design and synthesis of pyrazole antitumor compound containing amide bonds
The invention discloses pyrazole derivatives containing amide bonds, and a preparation method thereof. The structure of the pyrazole derivatives containing amide bonds is represented by a formula in the invention, wherein R1 is selected from groups disclosed in the invention, and R2 is selected from -CH3, -CH2CH3, and other groups disclosed in the invention.
-
Paragraph 0030; 0031; 0032

(2017/08/31)

Design and synthesis method of pyrazole ring-containing benzamide antineoplastic compounds
The invention discloses pyrazole ring-containing benzamide derivatives and a preparation method thereof. The pyrazole ring-containing benzamide derivatives have structures shown in the description. In the formula, R1 represents -CH3 and other groups shown
-
Paragraph 0032; 0034

(2017/09/26)

SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF
The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.
-
Paragraph 00077

(2015/03/13)

Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof
A five-and-six-membered heterocyclic compound as represented by general formula I, pharmaceutically acceptable salt, metabolite, metabolic precursors or drug precursors thereof, preparation method, pharmaceutical composition, and use thereof; the five-and-six-membered heterocyclic compound has activity as a Janus kinase (JAK) inhibitor, and can be used to prepare drugs for treating diseases caused by the abnormal activity of kinase, such as cell proliferation diseases like cancer.
-
Paragraph 0179; 0181

(2015/12/07)

HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF
Provided herein are novel heteroaromatic derivatives, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a prodrug, a pharmaceutically acceptable salt or a prodrug thereof, and pharmaceutical compositions containing such compounds. Also provided herein are uses of such compounds or pharmaceutical compositions thereof in the manufacture of a medicament for treating respiratory diseases, especially chronic obstructive pulmonary disease (COPD).
-
Paragraph 00770

(2015/11/10)

IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE DERIVATIVES AS KINASE JAK-2 INHIBITORS
A compound represented by the general formula (I) wherein R1represents H or C1-C4 alkyl; R2 represents phenyl substituted with one or two substituents selected from the group consisting of halogen atom and OCsu
-
Page/Page column 38-39

(2014/02/16)

Arylazopyrazoles: Azoheteroarene photoswitches offering quantitative isomerization and long thermal half-lives
Arylazopyrazoles, a novel class of five-membered azo photoswitches, offer quantitative photoswitching and high thermal stability of the Z isomer (half-lives of 10 and ～1000 days). The conformation of the Z isomers of these compounds, and also the arylazop
Weston, Claire E.,Richardson, Robert D.,Haycock, Peter R.,White, Andrew J. P.,Fuchter, Matthew J.
supporting information
p. 11878 - 11881
(2014/11/08)

Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives
The c-jun N-terminal kinase 3 (JNK3) is expressed primarily in the brain. Numerous reports have shown that inhibition of JNK3 is a promising strategy for treatment of neurodegeneration. The optimization of aminopyrazole-based JNK3 inhibitors with improved potency, isoform selectivity, and pharmacological properties by structure-activity relationship (SAR) studies utilizing biochemical and cell-based assays, and structure-based drug design is reported. These inhibitors had high selectivity over JNK1 and p38α, minimal cytotoxicity, potent inhibition of 6-OHDA-induced mitochondrial membrane potential dissipation and ROS generation, and good drug metabolism and pharmacokinetic (DMPK) properties for iv dosing. 26n was profiled against 464 kinases and was found to be highly selective hitting only seven kinases with >80% inhibition at 10 μM. Moreover, 26n showed good solubility, good brain penetration, and good DMPK properties. Finally, the crystal structure of 26k in complex with JNK3 was solved at 1.8 ? to explore the binding mode of aminopyrazole based JNK3 inhibitors.
Zheng, Ke,Iqbal, Sarah,Hernandez, Pamela,Park, Hajeung,Lograsso, Philip V.,Feng, Yangbo
supporting information
p. 10013 - 10030
(2015/02/19)

PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS JAK INHIBITORS
The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z4, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the tre
-
Page/Page column 45

(2013/03/26)

8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS
Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus
-
Page/Page column 107

(2013/09/12)

HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS
The present invention relates to compounds of formula (I), wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis
-
Page/Page column 71; 72

(2014/01/07)

PYRIDINE COMPOUNDS AND AZA ANALOGUES THEREOF AS TYK2 INHIBITORS
The present invention relates to compounds of formula (I), wherein R1 to R3, X1, X2 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
-
Page/Page column 48

(2012/05/31)

(7H-PYRROLO[2,3-D]PYRIMIDIN-2-YL)AMINE COMPOUNDS AS JAK3 INHIBITORS
The present invention relates to compounds of formula (I) wherein X1 to X5, Y, and Z1 to Z3 have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
-
Page/Page column 40

(2012/11/07)

PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
-
Page/Page column 160-161

(2011/10/19)

PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY
Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.
-
Page/Page column 49

(2011/02/15)

PYRAZOLE COMPOUNDS AS JAK INHIBITORS
The present invention relates to compounds of formula (I), wherein R1, R2, R1a, R1b have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
-
Page/Page column 36

(2011/11/13)

[1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS
Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a Formula represented by the following: (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, joint disease, inflammation, and others.
-
Page/Page column 60

(2010/04/03)

QUINOLINE DERIVATIVES
The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
-
Page/Page column 42

(2009/04/24)

QUINOLINE DERIVATIVES
The invention concerns quinoline derivatives of Formula (I): or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
-
Page/Page column 109-110

(2008/06/13)

QUINAZOLINE DERIVATIVES
The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
-
Page/Page column 113

(2008/06/13)

QUINOLINE DERIVATIVES FOR TREATING CANCER
The invention concerns quinoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
-
Page/Page column 101

(2008/06/13)

NAPHTHYRIDINE DERIVATIVES
The invention concerns naphthyridine derivatives of Formula (Ia) or (Ib) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, G1, G2, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders or disease states associated with angiogenesis and/or vascular permeability.
-
Page/Page column 158

(2010/11/28)

NAPHTHYRIDINE DERIVATIVES AS ANTI-CANCER AGENTS
The invention concerns naphthyridine derivatives of Formula (I): or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, G1, G2, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders or disease states associated with angiogenesis and/or vascular permeability.
-
Page/Page column 101

(2010/11/28)

QUINAZOLINE DERIVATIVES
The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.
-
Page/Page column 123

(2008/06/13)

(2-imidazolin-2-yl) fused heteropyridine compounds, intermediates for the preparation of and use of said compounds as herbicidal agents
There are provided novel (2-imidazolin-2-yl) fused heteropyridine compounds, and intermediate compounds for the preparation thereof, and a method for controlling a wide variety of annual and perennial plant species therewith.
-
(2008/06/13)

Basicity of Azoles. VII. Basicity of C-Aminopyrazoles in Relation to Tautomeric and Protonation Studies
The pKa values of five aminopyrazoles were determined.The aqueous basicities are discussed in terms of tautomerism (72percent of 3-amino tautomer), protonation site (only 4-aminopyrazoles protonate on the amino group) and amino substituent effects.The results of theoretical calculations, carried out at the semiempirical INDO level, iniciate that in the gas phase 3- and 5-aminopyrazoles protonate on the pyrazolic nitrogen atom, whereas 4-aminopyrazoles possess similar proton affinities for both nitrogen atoms (pyrazolic and amino).
Catalan, Javier,Menendez, Margarita,Laynez, Jose,Claramunt, Josa Maria,Bruix, Marta,et al.
p. 997 - 1000
(2007/10/02)